Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价三贝苎鼾胶囊治疗阻塞性睡眠呼吸暂停低通气综合征(痰瘀互结证)有效性和安全性的多中心、随机、双盲、安慰剂平行对照Ⅲ期临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of Sanbei Zhuhan Capsule in the treatment of obstructive sleep apnea-hypopnea syndrome (phlegm and blood stasis syndrome)
以用药第 4周呼吸暂停低通气指数 (AHI)应答率 为主要疗效指标,以安慰剂为对照, 确证三贝苎鼾胶囊治疗阻塞性睡眠呼吸暂停低通气综合征的有效性和安全性。
[Translation] The apnea-hypopnea index (AHI) response rate at the 4th week of medication was used as the primary efficacy indicator, and placebo was used as the control to confirm the effectiveness and safety of Sanbei Zhuhan Capsule in the treatment of obstructive sleep apnea-hypopnea syndrome.
三贝苎鼾胶囊治疗阻塞性睡眠呼吸暂停低通气综合征(痰瘀互结证)临床试验
[Translation] Clinical trial of Sanbei Zhuhan capsule in the treatment of obstructive sleep apnea-hypopnea syndrome (phlegm and blood stasis syndrome)
评价三贝苎鼾胶囊治疗阻塞性睡眠呼吸暂停低通气综合征(痰瘀互结证)的有效性及临床应用的安全性。
[Translation] To evaluate the efficacy and safety of Sanbei Zhuhan Capsule in the treatment of obstructive sleep apnea-hypopnea syndrome (phlegm and blood stasis syndrome).
100 Clinical Results associated with Dongyang Baorentang Pharmaceutical Co., Ltd. Beijing Technology Branch
0 Patents (Medical) associated with Dongyang Baorentang Pharmaceutical Co., Ltd. Beijing Technology Branch
100 Deals associated with Dongyang Baorentang Pharmaceutical Co., Ltd. Beijing Technology Branch
100 Translational Medicine associated with Dongyang Baorentang Pharmaceutical Co., Ltd. Beijing Technology Branch